Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?

If you’re looking for some solid reasons for Takeda CEO Christophe Weber’s relentless pursuit of a $62 billion Shire buyout, you need look no further than the Japan-based company’s Q2 numbers.